Mallinckrodt (MNK) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Mallinckrodt (MNK) closed at $23.58, marking a -1.13% move from the previous day. This change lagged the S&P 500’s daily loss of 0.61%. Elsewhere, the Dow lost 0.72%, while the tech-heavy Nasdaq lost 0.56%.

Coming into today, shares of the specialty pharmaceutical company had gained 11.45% in the past month. In that same time, the Medical sector gained 2.13%, while the S&P 500 gained 5.68%.

MNK will be looking to display strength as it nears its next earnings release, which is expected to be May 7, 2019. The company is expected to report EPS of $1.79, up 36.64% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $777.46 million, up 35.78% from the year-ago period.

MNK’s full-year Zacks Consensus Estimates are calling for earnings of $8.22 per share and revenue of $3.26 billion. These results would represent year-over-year changes of +2.62% and +21.51%, respectively.

Investors should also note any recent changes to analyst estimates for MNK. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company’s business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.29% higher within the past month. MNK is currently sporting a Zacks Rank of #1 (Strong Buy).

Investors should also note MNK’s current valuation metrics, including its Forward P/E ratio of 2.9. This valuation marks a discount compared to its industry’s average Forward P/E of 6.58.

Investors should also note that MNK has a PEG ratio of 0.24 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock’s expected earnings growth rate. MNK’s industry had an average PEG ratio of 1.17 as of yesterday’s close.

The Medical – Generic Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 83, putting it in the top 33% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Mallinckrodt public limited company (MNK): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research
Source: Zacks



Leave a Reply